AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 6374402
Drug: Oral lithium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral lithium started at the time of biopsy‐proven hypoplasia
Trial: 30536081
Drug: Roflumilast 250
RxNorm normalized name: ROFLUMILAST 250MCG TAB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Roflumilast 250 μg daily
Trial: 30536081
Drug: Roflumilast 100
RxNorm normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Roflumilast 100 μg daily
Trial: 18556964
Drug: Recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Recombinant human growth hormone (rhGH) at a dosage of 0.067 mg/kg/day
Trial: 16087818
Drug: Full starting
RxNorm normalized name: venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Full starting dose of levothyroxine (1.6 mug/kg)
Trial: 16087818
Drug: Low starting
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low starting dose of levothyroxine (25 mug, increased every 4 weeks)
Trial: 12452231
Drug: Morphine 1
RxNorm normalized name: morphine 10 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 1 mg and droperidol 0.0625 mg
Trial: 10358538
Drug: Standardised protocol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardised protocol administered by senior nurses
Trial: 10649811
Drug: Conjugated equine
RxNorm normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conjugated equine estrogen (CEE), 0.625 mg/d
Trial: 7807658
Drug: CEE, 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE, 0.625 mg/d plus cyclic medroxyprogesterone acetate (MPA), 10 mg/d for 12 d/mo
Trial: 7807658
Drug: CEE, 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE, 0.625 mg/d plus consecutive MPA, 2.5 mg/d
Trial: 7807658
Drug: CEE, 0.625
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CEE, 0.625 mg/d plus cyclic micronized progesterone (MP), 200 mg/d for 12 d/mo
Trial: 8369511
Drug: Corticosteroids (prednisone,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroids (prednisone, 60 mg/day for 7 days, followed by tapering over 14 days)
Trial: 29792226
Drug: Regular occupational
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular occupational therapy
Trial: 25818388
Drug: Conventional control
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional control therapy
Trial: 22684431
Drug: 10 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg/kg abatacept plus MTX
Trial: 22684431
Drug: 2 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/kg abatacept plus MTX
Trial: 16800349
Drug: ICL670 (deferasirox)
RxNorm normalized name: Deferasirox
DrugBank: Deferasirox (DB01609)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: ICL670 (deferasirox) at a dose of 20 to 40 mg/kg
Trial: 15138373
Drug: Osteopathic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Osteopathic treatment (manual techniques including parietal, visceral, and craniosacral techniques)
Trial: 15138373
Drug: Orthopedic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orthopedic treatment (chiropractic techniques, antiphlogistics, and cortison injections)
Trial: 9655732
Drug: salmeterol 50
RxNorm normalized name: FLUTICAS 100/SALMETEROL 50 INHL DISK 14
FDA approved: no
EMA approved: no
PMDA approved: no
Description: salmeterol 50 microg twice daily (BDP400+salm)
Trial: 9655732
Drug: beclomethasone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: beclomethasone 200 microg twice daily (BDP800)
Trial: 9655732
Drug: placebo (BDP400)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (BDP400) in addition to beclomethasone 200 microg twice daily
Trial: 6097137
Drug: Atracurium 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium 0.4 mg/kg
Trial: 27312053
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with cisplatin (25 mg/m² on days 1 and 8), etoposide (60 mg/m² on days 1-3), and irinotecan (90 mg/m² on day 8) for five 2-week courses.
Trial: 27312053
Drug: Topotecan (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topotecan (1.0 mg/m² on days 1-5, every 3 weeks) for four courses.
Trial: 27312053
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy group
Trial: 20636485
Drug: l‐NMMA (NO
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l‐NMMA (NO synthase inhibitor)
Trial: 20636485
Drug: Phenylephrine (α‐receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (α‐receptor agonist)
Trial: 20178604
Drug: Bright light
RxNorm normalized name: kaolin light
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright light therapy (approximately 10,000 lux for two half-hour sessions daily)
Trial: 20178604
Drug: Placebo (approximately
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (approximately 300 lux for two half-hour sessions daily)
Trial: 18502107
Drug: Lignan complex
RxNorm normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lignan complex (500 mg/d of secoisolariciresinol diglucoside)
Trial: 15918387
Drug: Propacetamol 2
RxNorm normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propacetamol 2 g + Ketoprofen 100 mg
Trial: 10085472
Drug: melatonin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: melatonin (various doses)
Trial: 31077798
Drug: AOMI+PAIN (AOMI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOMI+PAIN (AOMI during hypertonic saline injection)
Trial: 31077798
Drug: PAIN (rest
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PAIN (rest for 10 minutes after hypertonic saline injection)
Trial: 26293163
Drug: Tabalumab 120
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 120 mg every 2 weeks (120 Q2W)
Trial: 26293163
Drug: Tabalumab 120
RxNorm normalized name: Tabalumab
DrugBank: Tabalumab (DB11657)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tabalumab 120 mg every 4 weeks (120 Q4W)
Trial: 19733721
Drug: Naproxcinod 750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxcinod 750 mg twice daily
Trial: 19733721
Drug: Naproxcinod 375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naproxcinod 375 mg
Trial: 17531690
Drug: Intracameral cefuroxime
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracameral cefuroxime prophylaxis at 1 mg in 0.1 mL normal saline
Trial: 15262827
Drug: Aprotinin (2x10(6)
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aprotinin (2x10(6) KIU in pump prime, 2x10(6) KIU loading dose, followed by 0.5x10(6) KIU/h
Trial: 9850898
Drug: Topical tetracaine
RxNorm normalized name: tetracaine Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine 0.5% plus intracameral lidocaine 1%
Trial: 9850898
Drug: Topical tetracaine
RxNorm normalized name: tetracaine Topical Ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical tetracaine 0.5% plus intracameral BSS
Trial: 3377945
Drug: pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 1 mg kg‐1 i.v.
Trial: 3377945
Drug: pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 1 mg kg‐1 i.m.
Trial: 3377945
Drug: pethidine 1
RxNorm normalized name: Pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pethidine 1 mg kg‐1 rectally
Trial: 28460544
Drug: Early low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early low dose aprotinin
Trial: 28460544
Drug: Late low
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late low dose aprotinin
Trial: 25441397
Drug: Atorvastatin 80
RxNorm normalized name: atorvastatin 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 80 mg daily for 12 weeks
Trial: 22692637
Drug: Metformin (MET)
RxNorm normalized name: metformin / pioglitazone Oral Tablet [Actoplus Met]
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (MET) 850 mg twice daily
Trial: 20110592
Drug: Complex antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex antioxidant blend (active treatment) for four months
Trial: 20110592
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment (identical gel and bottle) for four months
Trial: 20110592
Drug: Complex antioxidant
RxNorm normalized name: antioxidant 119
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Complex antioxidant blend (active treatment)
Trial: 16136166
Drug: Chemotherapy (without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (without donor)
Trial: 11903940
Drug: Single Shot
RxNorm normalized name: ACL7 SINGLE SHOT EPIDURAL KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single Shot (SS) technique with 0.25 ml x kg(‐1) of 0.25% bupivacaine
Trial: 11903940
Drug: Double Shot
RxNorm normalized name: ChoreMate One-Shot
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double Shot (DS) technique with one-third of total dose of bupivacaine given as SS and remaining two-thirds deposited above and lateral to mid‐inguinal point
Trial: 9508163
Drug: Radiotherapy plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy plus chemotherapy
Trial: 2116082
Drug: CA 300
RxNorm normalized name: Lyrica 300mg Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 300 mg alone
Trial: 2116082
Drug: CA 200
RxNorm normalized name: DCA 2000 Normal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 200 mg + mitomycin C (MMC) 10 mg
Trial: 2116082
Drug: CA 180
RxNorm normalized name: Ca 2+
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CA 180 mg + adriamycin (ADM) 20 mg
Trial: 387225
Drug: cis‐dichlorodiammineplatinum(II) (cis‐platinum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 30 mg/m2
Trial: 387225
Drug: cis‐dichlorodiammineplatinum(II) (cis‐platinum)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cis‐dichlorodiammineplatinum(II) (cis‐platinum) at doses of 100 mg/m2
Trial: 387225
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorambucil and cis‐platinum (regimen B)
Trial: 387225
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of chlorambucil, cis‐platinum, and Adriamycin (regimen C)
Trial: 16096124
Drug: Non-preferred treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-preferred treatment
Trial: 17107904
Drug: Chlorambucil 20
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil 20 mg m‐2 for 3 days and dexamethasone 4 mg bd for 5 days plus oral idarubicin 10 mg m‐2 for 3 days (CID)
Trial: 17107904
Drug: Chlorambucil 20
RxNorm normalized name: Chlorambucil
DrugBank: Chlorambucil (DB00291)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chlorambucil 20 mg m‐2 for 3 days and dexamethasone 4 mg bd for 5 days (CD)
Trial: 11768840
Drug: Cefprozil (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefprozil (15 mg/kg per day in 2 divided doses for 10 days)
Trial: 11768840
Drug: Erythromycin (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (30 mg/kg per day in 3 divided doses for 10 days)
Trial: 3307308
Drug: Metoprolol (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (3.0 mg i.v. bolus followed by an i.v. infusion of 4.8 mg/h)
Trial: 3307308
Drug: Insulin (2.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin (2.4 U/h i.v. infusion over 180 min)
Trial: 31702602
Drug: Nicotine replacement
RxNorm normalized name: Nicotine
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine replacement therapy (NRT) and telephone counseling
Trial: 23683751
Drug: MAL-PDT (methylaminolevulinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL-PDT (methylaminolevulinate photodynamic therapy; two sessions with an interval of 1 week)
Trial: 23683751
Drug: Imiquimod cream
RxNorm normalized name: Imiquimod Cream
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Imiquimod cream (once daily, five times a week for 6 weeks)
Trial: 23683751
Drug: Fluorouracil cream
RxNorm normalized name: Fluorouracil Cream
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fluorouracil cream (twice daily for 4 weeks)
Trial: 16083385
Drug: Korean MMPI-2
RxNorm normalized name: Korean ginseng
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Korean MMPI-2 L, K, and S scales
Trial: 7675553
Drug: Control treatment
RxNorm normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control treatment (CONT)
Trial: 1974429
Drug: Flutoprazepam 4
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutoprazepam 4 mg
Trial: 1974429
Drug: Flutoprazepam 2
RxNorm normalized name: flunitrazepam
DrugBank: Flunitrazepam (DB01544)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutoprazepam 2 mg
Trial: 7323625
Drug: Tiapride (300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tiapride (300 mg/day orally for 30 days)
Trial: 31865235
Drug: Multiple Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Exposure treatment condition (at least 15 activities, exposed once)
Trial: 31865235
Drug: Repeated Exposure
RxNorm normalized name: eicosyl povidone (2 eicosyl branches-repeat)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated Exposure treatment condition (3 activities, exposed during five sessions each)
Trial: 31865235
Drug: Multiple Exposure
RxNorm normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple Exposure treatment condition
Trial: 24337659
Drug: Propofol (2-3.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol (2-3.5 μg/ml)
Trial: 23174584
Drug: Regular dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Regular dose atorvastatin
Trial: 19999921
Drug: Fast track
RxNorm normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fast track group (epidural analgesia, early ambulation, oral feeding)
Trial: 19999921
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no epidural analgesia, early ambulation, early oral diet)
Trial: 16889491
Drug: T(4) treatment
RxNorm normalized name: 4-T-BUTYLCYCLOHEXANOL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T(4) treatment in DS infants (N = 99)
Trial: 16889491
Drug: Placebo treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo treatment in DS infants (N = 97)
Trial: 21111365
Drug: Tenecteplase (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenecteplase (up to 2 mg) administered intraluminally, with a second dose if indicated and a third placebo dose.
Trial: 21111365
Drug: Placebo followed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo followed by up to two doses of tenecteplase if needed.
Trial: 15675979
Drug: Amino acids
RxNorm normalized name: Amino acids
DrugBank: Amino acids (DB09393)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acids (500 ml intravenously during 4 h)
Trial: 15675979
Drug: Ringer's solution
RxNorm normalized name: Ringer's solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ringer's solution (500 ml intravenously during 4 h)
Trial: 12166794
Drug: Triple dye
RxNorm normalized name: Triple Dye
DrugBank: Brilliant green cation (DB11279)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple dye once followed by daily alcohol application
Trial: 12166794
Drug: Daily alcohol
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily alcohol application alone
Trial: 2281848
Drug: Midazolam (0.2-0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (0.2-0.3 mg/kg b.w. i.v., group I n = 10)
Trial: 2281848
Drug: Diazepam (0.3-0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diazepam (0.3-0.4 mg/kg b.w., i.v., group II n = 10)
Trial: 2281848
Drug: Flunitrazepam (0.03-0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flunitrazepam (0.03-0.04 mg/kg b.w., i.v., group III n = 10)
Trial: 23890856
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (total omega-3 6 g/d)
Trial: 19246952
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral intake of 300 mg alpha‐tocopheryl‐acetate for 2 months
Trial: 10753003
Drug: Sleep restriction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sleep restriction therapy combined with sleep hygiene
Trial: 10753003
Drug: Nap modification
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nap modification of sleep restriction therapy combined with sleep hygiene
Trial: 8631189
Drug: Grapefruit juice
RxNorm normalized name: grapefruit juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grapefruit juice (naringin, 887 mg/ml)
Trial: 1420493
Drug: Phosphatidylcholine premixed
RxNorm normalized name: phosphatidylcholine, soybean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phosphatidylcholine premixed dialysis solution
Trial: 1420493
Drug: Control dialysis
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control dialysis solution
Trial: 31451013
Drug: everolimus-eluting drug-eluting
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: everolimus-eluting drug-eluting stents (DES)
Trial: 24585000
Drug: Postpartum oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postpartum oxytocin infusion of 80 U/500 mL over 1 hour
Trial: 24585000
Drug: Postpartum oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postpartum oxytocin infusion of 80 U/500 mL over 8 hours
Trial: 16375199
Drug: Inhaled short-acting
RxNorm normalized name: Sinex Long-Acting Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled short-acting beta2 agonist
Trial: 7951277
Drug: Treatment group
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment group (with side effects)
Trial: 7951277
Drug: Treatment noncompliers
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment noncompliers
Trial: 7951277
Drug: Hypothetical scenario
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypothetical scenario with treatment compliance equal to placebo compliance
Trial: 23510037
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab, treated as needed every 4 weeks (cohort A)
Trial: 23510037
Drug: 2.0 mg
RxNorm normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.0 mg ranibizumab, treated as needed every 6 weeks (cohort B)
Trial: 21279645
Drug: Wheat flour
RxNorm normalized name: Wheat Flour
DrugBank: Wheat (DB10579)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wheat flour inhalation
Trial: 21279645
Drug: Rye flour
RxNorm normalized name: Rye
DrugBank: Rye (DB10564)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rye flour inhalation
Trial: 1593216
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg two times a day) with dimethyl sulfoxide (500 mg four times daily)
Trial: 1593216
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg two times a day) with allopurinol (50 mg four times a day)
Trial: 1593216
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg two times a day)
Trial: 6095659
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg at bedtime)
Trial: 1593216
Drug: Cimetidine (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (400 mg two times a day) with dimethyl sulfoxide or allopurinol
Trial: 29193877
Drug: Probiotic treatment
RxNorm normalized name: Rezyst Probiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic treatment for 10 days
Trial: 25019115
Drug: Orabase treatment
RxNorm normalized name: ORABASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orabase treatment
Trial: 23449351
Drug: FOLFOX/XELOX plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFOX/XELOX plus cediranib 20 mg (HORIZON II)
Trial: 23449351
Drug: mFOLFOX6 plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFOX6 plus cediranib 20 mg (HORIZON III)
Trial: 19898259
Drug: Docetaxel/cisplatin/fluorouracil (TPF)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Docetaxel/cisplatin/fluorouracil (TPF) combination chemotherapy
Trial: 17045905
Drug: 40 g
RxNorm normalized name: PEG-40 GLYCERYL STEARATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 g walnuts